

A Roche Lung Experts Asia Pacific (LEAP) initiative

**NSCLC treatment landscape –
LEAP speaker tour**
Bringing evidence into clinical practice

Disclaimers: The content in this meeting is intended for educational purposes only and may contain information about non-approved products, indications, or experimental drugs in development and should not be misconstrued as a recommendation for use.

Healthcare professionals must refer to the local prescribing information for the respective products for approved indications in their country.

This invitation is valid for healthcare professionals only. Other accompanying persons are not invited to attend.

Meeting details

Date: Thursday 21 January

Venue: Pullman Bangkok Hotel

Time: 17:30–21:00

Dear Colleagues,

It is our pleasure to invite you to this Roche-sponsored educational meeting, *NSCLC treatment landscape – LEAP speaker tour: bringing evidence into clinical practice*.

Approximately 85% of lung cancer cases are NSCLC.¹ The Southeast Asian and Western Pacific regions accounted for approximately 1 million of 1.8 million cases worldwide in 2012.¹ Lung cancer is a disease with poor prognosis; however in recent years the development of targeted therapies has revolutionised its treatment, providing patients with significant improvement in disease outcome and quality of life.^{2–4} With the increase in availability of targeted therapies in Asia, there is hope that more patients can be provided with the optimal treatment option for their disease and achieve improved outcomes.

At this meeting, the expert Faculty will provide an overview of targeted therapies for lung cancer with a focus on *EGFR* tyrosine kinase inhibitor and anti-angiogenic treatments, and will discuss their application in Asia and in clinical practice. We hope that you will find these topics informative and engaging, and look forward to a stimulating and productive meeting.

<insert signatory >

Dr. Touch Ativitavas

References: 1. Yatabe Y, et al. *J Thorac Oncol* 2015;10:438-45 ; 2. Forrest LM, et al. *Br J Cancer* 2005;93:977-8 ; 3. Antonicelli A, et al. *Int J Med Sci* 2013;10:320-30; 4. Ulahannan SV & Brahmer JR. *Cancer Invest* 2011;29:325-37.



Time	Topic
17:30–18:00	Coffee break
18:00–18:05	Opening and welcome <i>Dr. Touch Ativitavas</i>
18:05–18:45	Session 1: Tyrosine kinase inhibitor therapies in NSCLC patients (presentation followed by Q&A) <i>Professor Filippo de Marinis (Italy)</i>
18:45–19:25	Session 2: Anti-angiogenic therapies in NSCLC patients (presentation followed by Q&A) <i>Professor Filippo de Marinis (Italy)</i>
19:25–19:55	Session 3: Future therapies for NSCLC (presentation followed by Q&A) <i>Agnes C. I. Kiu Weber, MD (Regional Medical Leader, Roche APAC)</i>
19:55–21:00	Dinner

